133 related articles for article (PubMed ID: 35060242)
1. Influence of blood group and von Willebrand factor on population pharmacokinetics and dose individualization of recombinant factor VIII in Taiwanese patients with haemophilia A.
Singkham N; Punyawudho B; Yu MS; Cheng SN; Chen SH; Chang H; Chen CC; Hsiao CC; Hou JY; Fang YP; Wang HW; Lin JH; Yu LH; Chen YC
Haemophilia; 2022 Mar; 28(2):230-238. PubMed ID: 35060242
[TBL] [Abstract][Full Text] [Related]
2. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
Vargas Christensen I; Loftager M; Rode F; Mørck Nielsen H; Kreilgaard M; Larsen MS
J Thromb Haemost; 2019 Jun; 17(6):964-974. PubMed ID: 30924607
[TBL] [Abstract][Full Text] [Related]
3. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
Lalezari S; Martinowitz U; Windyga J; Enriquez MM; Delesen H; Schwartz L; Scharrer I
Haemophilia; 2014 Jan; 20(1):e15-22. PubMed ID: 24252058
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
[TBL] [Abstract][Full Text] [Related]
5. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
Nestorov I; Neelakantan S; Ludden TM; Li S; Jiang H; Rogge M
Clin Pharmacol Drug Dev; 2015; 4(3):163-74. PubMed ID: 27140796
[TBL] [Abstract][Full Text] [Related]
7. Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia.
Larsen MS; Juul RV; Groth AV; Simonsson USH; Kristensen AT; Knudsen T; Agersø H; Kreilgaard M
Eur J Pharm Sci; 2018 Mar; 115():196-203. PubMed ID: 29369801
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients.
Karafoulidou A; Suarez E; Anastasopoulou I; Katsarou O; Kouramba A; Kotsi P; Zografidis A; Lukas JC
Eur J Clin Pharmacol; 2009 Nov; 65(11):1121-30. PubMed ID: 19641914
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
[TBL] [Abstract][Full Text] [Related]
11. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
[TBL] [Abstract][Full Text] [Related]
12. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery.
Di Paola J; Lethagen S; Gill J; Mannucci P; Manco-Johnson M; Bernstein J; Nichols WL; Bergman GE
Haemophilia; 2011 Sep; 17(5):752-8. PubMed ID: 21689209
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A.
Dmoszynska A; Hellmann A; Baglin T; O'Shaugnessy D; Trelinski J; Kuliczkowski K; Kloczko J; Hay C; Zawilska K; Makris M; Shaikh-Zaidi R; Gascoigne E; Dash C
Haemophilia; 2011 Mar; 17(2):185-90. PubMed ID: 21070496
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration.
de Jager NCB; Heijdra JM; Kieboom Q; Kruip MJHA; Leebeek FWG; Cnossen MH; Mathôt RAA;
Thromb Haemost; 2020 Oct; 120(10):1407-1416. PubMed ID: 32746466
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
[TBL] [Abstract][Full Text] [Related]
16. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.
Tagliaferri A; Matichecchia A; Rivolta GF; Riccardi F; Quintavalle G; Benegiamo A; Rossi R; Coppola A
Blood Transfus; 2020 Sep; 18(5):374-385. PubMed ID: 31855153
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects.
Katragadda S; Neelakantan S; Diao L; Wong N
J Clin Pharmacol; 2021 Jul; 61(7):889-900. PubMed ID: 33719084
[TBL] [Abstract][Full Text] [Related]
18. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.
Gill JC; Castaman G; Windyga J; Kouides P; Ragni M; Leebeek FW; Obermann-Slupetzky O; Chapman M; Fritsch S; Pavlova BG; Presch I; Ewenstein B
Blood; 2015 Oct; 126(17):2038-46. PubMed ID: 26239086
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of von Willebrand factor and factor VIII in canine von Willebrand disease and haemophilia A.
Stokol T; Trepanier L; Parry BW; Finnin BC
Res Vet Sci; 1997; 63(1):23-7. PubMed ID: 9368952
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease.
Bukkems LH; Heijdra JM; de Jager NCB; Hazendonk HCAM; Fijnvandraat K; Meijer K; Eikenboom JCJ; Laros-van Gorkom BAP; Leebeek FWG; Cnossen MH; Mathôt RAA
Blood Adv; 2021 Mar; 5(5):1513-1522. PubMed ID: 33683340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
